Serial Assessment of Immune Status by Circulating CD8+ Effector T Cell Frequencies for Posttransplant Infectious Complications
Table 2
Frequencies of Posttransplant Infection, Complication and Mortality in 3 Groups.
Group
Primary disease
Total
Infection
Rejection
LTC*
Hospital death
Bacteria
Virus
Fungus
(%)
(%)
(%)
(%)
(%)
(%)
(%)
I
Nonviral
14
5
2
5
2
4
1
1
HBV
6
0
0
0
0
0
0
0
HCV
11
4
2
3
0
0
0
0
Total
31
9 (29.0)
4 (12.9)
8 (25.8)
2 (6.5)
4 (12.9)
1 (3.2)
1 (3.2)
II
Nonviral
9
5
4
2
0
2
0
0
HBV
12†
3†
3†
2†
0
5
1†
1†
HCV
13†
4†
3†
4†
2
4
2†
3†
Total
33
11 (33.3)
9 (27.3)
7 (21.2)
2 (6.1)
11 (33.3)
2 (6.1)
3 (9.1)
III
Nonviral
6
5
4
5
3
2
1
1
HBV
6
4
2
3
0
1
0
0
HCV
16
9
5
5
3
5
2
2
Total
28
18 (64.3)
11(39.3)
13 (46.4)
6 (21.4)
8 (28.6)
3 (10.7)
3 (10.7)
All
—
.0117
.0690
.0812
.0985
.1472
.5038
.5131
I versus II
—
.7908
.2168
.7711
>.999
.0773
>.999
.6136
I versus III
—
.0092
.0346
.1124
.1337
.1974
.3373
.3373
II versus III
—
.0215
.4141
.0533
.1272
.7847
.6533
>.999
*LTC, Life-threatening infectious complication; †one recipient had HBV- and HCV-infection; ‡P-values are based on chi-square test; §P-values are based on Fisher’s exact test.
